Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lefamulin versus moxifloxacin in adults with community-acquired bacterial pneumonia
NL-OMON43840Phase 3Active, not recruiting
- Sponsor
- Nabriva Therapeutics plc
- Start
- Feb 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lefamulin, moxifloxacin and linezolid in community acquired pneumonia (CAP) (2 arms), sponsored by Nabriva Therapeutics plc. Primary endpoints: Early Clinical Response and Investigator's Assessment of Clinical Response at Test of Cure. Started Feb 2017; status: active, not recruiting.
02
Drugs
lefamulinmoxifloxacinlinezolid
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on NL-OMON43840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43840.